The race to commercialize humanoid robots in China is entering a new, high-stakes phase. The country’s top six humanoid robotics startups, collectively known in the industry as the “Six Little Dragons,” are rapidly accelerating their paths to initial public offerings, fueled by a massive influx of venture capital and significant technological breakthroughs in embodied AI. The sprint toward the public markets underscores the rapid maturation of a sector that, just two years ago, was still largely confined to research laboratories and trade show demonstrations.
Who Are the Six Little Dragons?
The “Six Little Dragons” is an informal designation that has gained wide currency in China’s tech investment community. According to 36kr’s analysis published May 21, the label refers specifically to the six companies whose simultaneous push toward the public markets has defined the sector’s current moment: Unitree Technology (宇树科技), ZhiYuan Robot (智元机器人), UBTECH Robotics (优必选), Leju Robot (乐聚机器人), Fourier Intelligence (傅利叶智能), and Xingdong Jiyuan (星动纪元). Each has carved out a distinct niche within the broader humanoid robot ecosystem, from industrial automation to service applications, and each is at a different stage of its journey toward the public markets.
The financial profiles of the six companies are strikingly divergent, reflecting the highly differentiated nature of the sector. At one end stands Unitree, which the 36kr analysis describes as “an outstanding student with relatively comprehensive profitability.” Unitree’s revenue in 2025 reached 1.708 billion yuan, a year-on-year increase of 335%, with a net profit after deducting non-recurring items of 600 million yuan and a gross profit margin of 60.27%. The company’s shipment volume of humanoid robots exceeded 5,500 units in 2025, ranking first in the world. Its business model is built around selling general robot hardware platforms, rather than customized solutions, to scientific research institutions and universities, who are not price-sensitive and purchase the hardware for secondary development and algorithm training.
ZhiYuan’s Mass-Production Breakthrough and UBTECH’s Industrial Pivot
ZhiYuan Robot represents a different model: what 36kr calls the “mass-production school.” In March 2026, its 10,000th general embodied robot, the Expedition A3, rolled off the production line, a milestone reached just three months after the 5,000-unit mark. Chairman Deng Taihua has stated that the company’s revenue in 2025 exceeded 1.05 billion yuan, making it “the fastest robot company in China to achieve 1 billion yuan in revenue.” ZhiYuan has completed 11 rounds of financing; after its Series B round in March 2025, its post-investment valuation reached 15 billion yuan, led by Tencent. The market expects a Hong Kong IPO in 2026 at a target valuation of 40–50 billion Hong Kong dollars.
UBTECH, already listed on the Hong Kong Stock Exchange since late 2023, is the only one of the six that is already a public company. Its revenue in 2025 was 2.001 billion yuan, a 53% year-on-year increase, though it posted a net loss of 790 million yuan. The more significant signal is operational: it delivered 1,079 full-size humanoid robots in 2025, a year-on-year increase of 358 times, generating 821 million yuan in revenue from that business line, a 22-fold surge that pushed it past the company’s legacy education robot division to become its largest revenue source. UBTECH is betting heavily on automotive manufacturing, with robots deployed at BYD, Geely, Mercedes-Benz, and Audi for assembly, inspection, and handling tasks.
The Smaller Three: Leju, Fourier, and Xingdong Jiyuan
Leju Robot is climbing steadily but has not yet reached profitability. Its revenue in 2025 was 258 million yuan, up approximately 365% year-on-year, with its “Kua Fu” series of full-size humanoid robots contributing 178 million yuan of that total at an average selling price of 308,100 yuan per unit. The company’s valuation stands at 4.327 billion yuan — the lowest among the six — and it is not expected to turn a profit until as early as 2028. Its IPO application on the Growth Enterprise Market was accepted on May 19, making it the first enterprise to use the fourth set of listing standards on that market.
Fourier Intelligence completed its Series E financing in early 2025 with investors including SoftBank and IDG Capital, at a valuation of approximately 8 billion yuan. Xingdong Jiyuan completed nearly 2.5 billion yuan in financing between March and April 2026, pushing its valuation above 10 billion yuan, and began mass-delivering thousands of units in the second quarter of 2026 across more than 10 logistics centers in cooperation with China Post and SF Express. Neither company has released comprehensive public financial data, and the real test from capital markets is still ahead.
A Record-Breaking Investment Environment
The IPO sprint is underpinned by a funding environment that has set new records. In the first four months of 2026 alone, there were 332 financing events for Chinese robot companies, totaling 61.307 billion yuan; 55 of those events specifically targeted humanoid robots, totaling 25.922 billion yuan. As EastFrontier reported, China’s robotics industry attracted a record $3.3 billion in the first quarter of 2026 alone. This capital is flowing from traditional venture capital firms, state-backed industrial funds, and major technology conglomerates including Alibaba, Tencent, and Baidu. The influx is enabling the “Six Little Dragons” to make the critical transition from R&D to mass production, with companies investing in dedicated manufacturing facilities such as China’s first automated humanoid robot factory in Guangdong, capable of producing one robot every 30 minutes.
The Road to the Public Markets
The push for IPOs is driven by the immense capital requirements of scaling hardware manufacturing and continuing intensive AI research simultaneously. Going public provides these companies with the war chests necessary to compete globally, particularly against well-funded U.S. rivals. The success of these IPOs will also serve as a critical validation signal for the entire sector, demonstrating to global investors that China’s humanoid robotics industry has moved beyond the hype cycle and into genuine commercial viability.
However, as the 36kr analysis makes clear, investors will be scrutinizing these companies carefully. The key questions will center on actual deployment metrics, revenue generation, gross margins, and the reliability of robots in real-world conditions. The data already available reveals a stark divide: Unitree and ZhiYuan together account for approximately 80% of domestic shipment volume, forming a first echelon that is pulling away from the rest of the field. Companies that can demonstrate sustainable unit economics and a clear path to profitability, as Unitree already has, will be rewarded with premium valuations; those still in the concept-verification stage will face a much more skeptical reception.
The international dimension of this IPO wave should not be overlooked. As EastFrontier has reported, Unitree has already launched its most affordable humanoid robot globally via AliExpress, signaling its ambition to compete in international markets at accessible price points. If the “Six Little Dragons” can replicate in humanoid robotics the kind of global market penetration that Chinese companies have achieved in electric vehicles and consumer electronics, the implications for the competitive position of robotics companies in the U.S., Japan, and Europe will be profound.